Companies › Boehringer Ingelheim

Boehringer Ingelheim

Boehringer Ingelheim is listed as a company in Pharma & Medical Devices. It has filed 4 comment letters on 4 proposed federal rules in 2026, most often with the Centers for Medicare & Medicaid Services.

Type: Company
Industry: Pharma & Medical Devices
Comment letters: 4
Rules commented on: 4
First letter: 2026-02-25
Latest letter: 2026-09-02
Agencies most often: Centers for Medicare & Medicaid Services (3); Office of the Secretary (1)

Activity by year

20264

Letters

2026

Medicare Drug Price Negotiation Program and Medicare Prescription Drug Benefit Program

CMS-2026-2080Health and Human Services Department, Centers for Medicare & Medicaid Services · filed 2026-09-02

Read the letter ↗

Medicare and Medicaid Programs; Patient Protection and Affordable Care Act; Interoperability Standards and Prior Authorization for Drugs for Medicare Advantage Organizations, Medicaid Managed Care Plans, State Medicaid Agencies, Children's Health Insurance Program (CHIP) Agencies and CHIP Managed Care Entities, and Issuers of Qualified Health Plans on the Federally-Facilitated Exchanges

CMS-2026-1255Health and Human Services Department, Centers for Medicare & Medicaid Services, Office of the Secretary · filed 2026-06-29

Read the letter ↗

Global Benchmark for Efficient Drug Pricing (GLOBE) Model

CMS-2025-1889Health and Human Services Department, Centers for Medicare & Medicaid Services · filed 2026-02-25

Read the letter ↗

Guarding U.S. Medicare Against Rising Drug Costs (GUARD) Model

CMS-2025-1888Health and Human Services Department, Centers for Medicare & Medicaid Services · filed 2026-02-25

Read the letter ↗